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Abstract Binding of the receptor-associated protein (RAP) to
the newly identified putative sorting receptor, sortilin, was
analyzed by surface plasmon resonance analysis of recombinant
RAP and sortilin domains and compared with binding to megalin
and low density lipoprotein receptor-related protein (LRP). The
data show that the RAP-binding site in sortilin is localized in the
cysteine-rich lumenal part homologous to yeast vacuolar protein-
sorting 10 protein (Vps10p), and the sortilin-binding site in RAP
is localized in the carboxy-terminal domain III of the three
homologous domains in RAP. Whereas sortilin bound only RAP
domain III, megalin and LRP bound all RAP domains with the
functional affinity order: domain IIIs domain Is domain II.
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1. Introduction
Receptor-associated protein (RAP) is a 39^40 kDa intra-
cellular protein that binds to the cysteine-rich ligand-binding
low density lipoprotein (LDL) receptor class A repeats of
LDL receptor-related receptors [1^4]. RAP is mainly located
in the endoplasmic reticulum (ER) (about 70%) and Golgi
(about 24%) compartments, and only minor amounts are lo-
cated in endosomes [5]. Consistent with this, RAP has a C-
terminal HNEL motif that functions as an ER retention sig-
nal [6]. RAP competes for ligand binding to all the LDL
receptor family proteins [7].
Gene knock-out studies have shown that cells lacking RAP
exhibit an approximately 75% reduction of the expression of
the K2-macroglobulin receptor/LDL receptor-related protein
(LRP), presumably because RAP prevents premature binding
of newly synthesized ligands to LRP and precipitation of the
receptor within the ER [8]. In addition, it has been reported
that soluble recombinant minireceptors comprising the clus-
ters of ligand-binding repeats in LRP were only secreted in
transfected cells when the cells were cotransfected with RAP
cDNA [9]. The retention of disul¢de-bonded receptor oligom-
ers in ER was reduced when the cells were cotransfected with
RAP.
RAP is a three-domain protein with an internal triplicate
sequence homology [4,10]. The autonomous regions of human
RAP comprise domain I (18^112), domain II (113^218), and
domain III (219^323). The solution structure of domain I (18^
112) was recently determined [11]. Domains I and III bind
independently to LRP [4,10,12] and domain III has been re-
ported to promote the correct folding and subsequent secre-
tion of the RAP-binding soluble ligand-binding regions of
LRP [4].
We have recently identi¢ed and isolated the cDNA of a
RAP-binding 95 kDa type I receptor designated sortilin [13],
which has no similarity to LDL receptor family receptors.
Sortilin consists of a large lumenal domain homologous to
each of two lumenal domains in yeast vacuolar protein-sort-
ing 10 protein (Vps10p) and a cytoplasmic tail with similarity
to that of the cation-independent mannose-6-phosphate recep-
tor. One function of Vps10p is to mediate the lysosomal sort-
ing of carboxypeptidase Y in yeast [14]. The Vps10p domain
is also present in sorLA [15], a recently described hybrid re-
ceptor of unknown function, which also contains a cluster of
11 LDL receptor type A repeats. The identical sequence of the
nine C-terminal residues of sortilin and the cation-independ-
ent mannose-6-phosphate receptor as well as the colocaliza-
tion of the two receptors in Golgi [13] and on the plasma
membrane further suggest a role of sortilin in protein sorting.
The aim of the present study was to de¢ne whether RAP
binds to the suggested ligand-binding lumenal domain, and
secondly to identify the RAP domain(s) involved in this in-
teraction. The three homologous RAP domains were analyzed
and compared with the binding to the giant LDL receptor
family receptors, megalin and LRP.
2. Materials and methods
2.1. Sortilin, RAP, megalin and LRP
The extracellular domain of sortilin was expressed by stable trans-
fection of Chinese hamster ovary (CHO) K-1 cells. The cDNA en-
compassing the N-terminal lumenal Vps10p domain plus a 6UHis tag
was ampli¢ed by PCR using the forward primer 5P-CGCCTCG-
AGCTGGCACACTCCACAGACC and the reverse primer 5P-GCG-
CGGCCGCCTAATGATGATGATGATGATGAGAATTTGACTT-
GGAAT. This PCR product, which contains an internal BspMII
restriction site, was cut with XhoI and NotI and ligated into the
pcDNA 3.1/Zeo3 vector from Invitrogen (San Diego, CA, USA).
Full-length sortilin cDNA in pBK-CMV [13] was cut out with XbaI
and BspMII and ligated into the same sites in the pcDNA 3.1/Zeo3
vector containing the PCR product. This created a cDNA encoding
the extracellular sortilin domain and a 6UHis tag. Stably transfected
CHO cell clones were established by limited dilution of transfected
cells using Zeocin (500 Wg/ml) for selection. The clone with highest
secretion was subcloned and grown in serum-free CHO cell medium
(HyQ-CCM 5 from Hyclone, Utah, USA). Secretion of the extracel-
lular sortilin domain into the medium of the clones was tested by
Western blotting using a rabbit polyclonal antibody generated against
an N-terminal peptide [13]. The extracellular domain was secreted as a
soluble protein and was e⁄ciently puri¢ed by RAP a⁄nity chroma-
tography as previously described for the puri¢cation of megalin [16].
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The yield was V2 Wg sortilin domain/ml medium. The identity of the
puri¢ed expression product was veri¢ed by microsequencing. Approx-
imately 5 Wg of soluble sortilin was subjected to SDS-gel electropho-
resis in a 8^16% polyacrylamide gel and electroblotted onto a poly-
vinylidene di£uoride membrane (Problot, Applied Biosystems). The
electroblotted band was cut out and subjected to Edman degradation
using an Applied Biosystems 477 A sequencer equipped with a 120 A
online chromatograph.
The sortilin cytoplasmic tail construct was made by PCR using full-
length sortilin cDNA as template for PWO polymerase (Boehringer
Mannheim) and 5P-CACGGATCCATCGAGGGTAGGAAGAAAT-
ATGTCTGTG-3P and 5P-TCAAGCTTATTCCAAGAGGTCCTCA-
TC-3P as NH2-terminal and COOH-terminal primer, respectively. Us-
ing the newly generated BamHI and HindIII sites, the PCR product
was subcloned into the Escherichia coli T7 expression vector,
sequenced and subsequently expressed in E. coli Bl21(DE3) cells.
The expressed 7.5 kDa hexa-His-tagged sortilin tail protein
(MGSHHHHHHSIEGRKYVCGGRFLVHRYSVLQQHAEANGV-
DGVDALDTASHTNKSGYHDDSDEDLLE) was puri¢ed on a
Ni2 nitrilotriacetic acid column as described previously [12].
Human RAP and the RAP constructs encompassing amino acid
residues 18^112 (domain 1), amino acid residues 113^218 (domain
II), amino acid residues 219^323 (domain III), domain I+II and do-
main II+III were produced as 6UHis-tagged constructs in E. coli as
previously described [10]. Megalin [16] and LRP [17] were puri¢ed
from rabbit kidney and human placenta, respectively, as described.
2.2. Surface plasmon resonance analysis
Analysis of the binding of RAP to puri¢ed recombinant sortilin was
performed by surface plasmon resonance measurements on a BIAcore
2000 instrument (Biosensor, Uppsala, Sweden). The BIAcore sensor
chips (type CM5, Biosensor) were activated with a 1:1 mixture of 0.2
M N-ethyl-NP-(3-dimethylaminopropyl) carbodiimide and 0.05 M N-
hydroxysuccinimide in water. RAP, sortilin, megalin and LRP were
immobilized at a concentration of 10^40 Wg/ml in 10 mM sodium
acetate, pH 3.5^4.5, and the remaining binding sites were blocked
with 1 M ethanolamine, pH 8.5. The estimated density of RAP, sor-
tilin, megalin and LRP was 24, 45, 37 and 24 fmol ligand/mm2, re-
spectively. The £ow cells were regenerated with 1.6 M glycine-HCl,
pH 3.0 (LRP and megalin) or 10 mM glycine-HCl, 20 mM EDTA,
500 mM NaCl, pH 4.0 (sortilin and RAP). The £ow bu¡er was 10
mM HEPES, 150 mM NaCl and 1.5 mM CaCl2, 1 mM EGTA pH
7.4. The binding data were analyzed using the BIAevaluation pro-
gram. The number of ligands bound per immobilized receptor was
estimated by dividing the ratio ‘RUligand/massligand’ with ‘RUreceptor/
massreceptor’.
3. Results
3.1. Expression of the Vps10p domain of sortilin as a
RAP-binding protein
Fig. 1 shows SDS-gel electrophoresis of the mannose-6-
phosphate receptor-like cytoplasmic tail of sortilin expressed
in E. coli and the cysteine-rich lumenal Vps10p domain of
sortilin expressed by stable transfection in CHO-K1 cells.
The lumenal sortilin domain was secreted into the medium
as a soluble protein. Binding of full-length RAP to this pro-
tein was readily demonstrated, since RAP a⁄nity chromatog-
raphy turned out to be an e⁄cient one-step procedure for
puri¢cation of the protein. Amino-terminal sequencing of
the secreted Vps10p sortilin domain revealed the sequence
Ser-Ala-Pro-Gly-Glu-Asp, thus demonstrating that the pro-
peptide had been cleaved o¡ by cleavage at the putative furin
recognition site preceding the recognized peptide sequence.
Surface plasmon analysis showed high-a⁄nity binding
(Kd = 76 nM) of the sortilin domain to immobilized RAP,
whereas no signi¢cant binding of the cytoplasmic tail was
evident (Fig. 2).
3.2. Binding of RAP domains to sortilin, megalin and LRP
In order to analyze the sortilin-RAP interaction, we per-
formed a comparative surface plasmon resonance analysis of
the binding of RAP and RAP domains to the Vps10p domain
of sortilin and puri¢ed LRP and megalin.
Fig. 3 shows the analysis of wild-type recombinant RAP
and RAP domains I, II and III. Only domain III displayed
binding to sortilin, whereas all domains bound to LRP and
megalin with the a⁄nity order: domain IIIs domain Is do-
main II. Table 1 shows the stoichiometry of the binding of
RAP, the single domains and the two-domain constructs. The
two-domain RAP constructs (domains I+II and II+III) exhib-
ited an increased functional a⁄nity for both megalin and LRP
(not shown) as compared to single domains, thus suggesting
simultaneous binding of both domains. This is also evident
from the dissociation curves (Fig. 3) showing that RAP dis-
sociates at a lower rate compared to the single domains. Each
of the tree RAP domains binds to multiple sites in LRP and
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Fig. 1. Reducing SDS-gel electrophoresis of the recombinant
Vps10p domain and cytoplasmic tail of sortilin. The cytoplasmic
tail was expressed as a 6UHis-tagged protein in E. coli and puri¢ed
by Ni2 a⁄nity chromatography. The Vps10p sortilin domain was
expressed as a secreted protein in CHO-K1 cells and puri¢ed by
RAP a⁄nity chromatography. The N-terminal sequence Ser-Ala-
Pro-Gly-Glu-Asp of the Vps10p domain demonstrates that the pro-
peptide of the Vps10p domain had been cleaved o¡.
Fig. 2. Surface plasmon resonance analysis of the binding of the
Vps10p sortilin domain (10 WM) and the cytoplasmic sortilin tail
(10 WM) to immobilized RAP. The binding curves of the Vps10p
domain were obtained in a concentration range of 0.01^10 WM and
¢tted to one-binding-site kinetics. The following constants were esti-
mated: kass = 1.8U104 M31 s31, kdiss = 1.39U1033 s31, Kd = 78 nM.
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megalin. Accordingly, the curves for RAP binding to megalin
and LRP did not ¢t to single-site kinetics.
Less than one RAP molecule was on average bound to
immobilized sortilin (Table 1) thus suggesting a 1:1 stoichi-
ometry. Accordingly, simple one-binding-site kinetics ¢tted to
the binding data of RAP. The estimated a⁄nity (Kd = 43 nM)
was close to that estimated in the inverse assay (Fig. 2). Do-
main I+II had no a⁄nity for sortilin and domain II+III had
no increased a⁄nity compared to domain III. The a⁄nity of
domain III was slightly higher (Kd = 30 nM) than wild-type
RAP, indicating that binding of RAP to sortilin is entirely
accounted for by domain III.
4. Discussion
The present study is a characterization of the binding of
sortilin to RAP, the only molecule so far known to bind to
the putative sorting receptor. The RAP-binding region was
mapped to the extracellular Vps10p-like lumenal domain
which was produced as a secreted and proteolytically proc-
essed recombinant protein in CHO-K1 cells and puri¢ed from
conditioned medium by RAP a⁄nity chromatography. The
sortilin-binding domain of RAP was mapped to domain III
by surface plasmon analysis of recombinant RAP domains.
Comparison with the binding of RAP to megalin and LRP
showed that sortilin, in contrast to these receptors, forms a
1:1 complex with RAP and binds to only one RAP domain.
Furthermore, our data and previous studies using radiola-
beled ligands [10] [4] have established that domain II, like
domains I and III, binds to both LRP and megalin and con-
tributes to the high-a⁄nity multisite interaction of single RAP
molecules with these receptors.
The binding of RAP is important for the processing of
LRP, and probably of megalin, as shown by Willnow et al.
[18] who observed that RAP-de¢cient mice process LRP less
e⁄ciently than normal mice. The molecular details are not
clear, but RAP is suggested to protect against ligand-induced
aggregation of the receptors, and in addition, RAP domain III
has been reported to be crucial for correct folding of LRP
minireceptors [4]. We are now investigating the importance of
RAP for processing of sortilin and assaying the RAP-binding
lumenal sortilin domain as an a⁄nity target for puri¢cation of
novel sortilin ligands.
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Fig. 3. Surface plasmon resonance analysis of the binding of re-
combinant human RAP and RAP domains I, II and III to the
Vps10p domain megalin and LRP. The concentration of RAP and
the RAP domains was 10 WM.
Table 1
The binding stoichiometry for binding of RAP and RAP domains to sortilin, megalin and LRP as measured by surface plasmon resonance
analysis after £ow in 600 s with 10 WM ligand, as shown in Fig. 3
kDa Ligand/sortilin Ligand/megalin Ligand/LRP
(mol/mol) (mol/mol) (mol/mol)
RAP domain I 16.1 0.04 1.09 1.42
RAP domain II 17.6 0.04 1.74 2.00
RAP domain III 17.4 0.35 2.77 3.50
RAP domain I+II 28.3 0.03 1.65 1.95
RAP domain II+III 29.9 0.28 2.85 3.51
RAP 37.7 0.23 2.06 2.82
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